Brian Gallagher


  • LocationBoston
  • ExpertiseVenture Capital


Mary-Ellen Craig

Tel: +1 781 466 8800

Brian has more than 20 years of investing, business development, operational and R&D experience in both biotechnology and large pharmaceutical companies. He joined Abingworth in 2018 and sources and supports deals across a wide range of therapeutic areas and stages of development from start-ups to late-stage venture capital investments. He was formerly a board member at Nimbus Therapeutics, Navitor Pharmaceuticals, River Vision (acquired by Horizon Pharma) and Translate Bio (NASDAQ: TBIO) amongst other companies and represents Abingworth on the boards of eFFECTOR and Q32 Bio.

Previously, Brian was a Partner at SR One, the venture capital arm of GlaxoSmithKline (GSK), where he established the company’s Boston office. Prior to SR One he was at Sirtris Pharmaceuticals where he was responsible for corporate development, operations and post-merger integration after the company’s acquisition by GSK. Earlier in his career, Brian held key roles in R&D at Alantos Pharmaceuticals (acquired by Amgen) and at Eisai. Brian holds a PhD in Organic Chemistry from the University of Michigan, is an inventor on over 25 patents and patent applications and is the senior author of a number of publications in prominent journals. He currently serves on the Investment Advisory Board for University of Michigan Biomedical Venture Fund, and the Advisory Board for NYU Medical School’s Therapeutic Alliances.